These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82. Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. Zamarin D; Wolchok JD Mol Ther Oncolytics; 2014; 1():14004. PubMed ID: 27119094 [TBL] [Abstract][Full Text] [Related]
83. Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells. Takasu A; Masui A; Hamada M; Imai T; Iwai S; Yura Y Cancer Gene Ther; 2016 Apr; 23(4):107-13. PubMed ID: 26987291 [TBL] [Abstract][Full Text] [Related]
84. Danger signalling during cancer cell death: origins, plasticity and regulation. Garg AD; Martin S; Golab J; Agostinis P Cell Death Differ; 2014 Jan; 21(1):26-38. PubMed ID: 23686135 [TBL] [Abstract][Full Text] [Related]
85. Recombinant Poxvirus and the Tumor Microenvironment: Oncolysis, Immune Regulation and Immunization. Sharp DW; Lattime EC Biomedicines; 2016; 4(3):. PubMed ID: 28191451 [TBL] [Abstract][Full Text] [Related]
86. Stimulation of dendritic cells by DAMPs in ALA-PDT treated SCC tumor cells. Wang X; Ji J; Zhang H; Fan Z; Zhang L; Shi L; Zhou F; Chen WR; Wang H; Wang X Oncotarget; 2015 Dec; 6(42):44688-702. PubMed ID: 26625309 [TBL] [Abstract][Full Text] [Related]
88. Tumor cell lysates as immunogenic sources for cancer vaccine design. González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929 [TBL] [Abstract][Full Text] [Related]
89. Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy. Rapoport BL; Anderson R Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30813267 [TBL] [Abstract][Full Text] [Related]
90. Impact of Autophagy in Oncolytic Adenoviral Therapy for Cancer. Tazawa H; Kuroda S; Hasei J; Kagawa S; Fujiwara T Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28698504 [TBL] [Abstract][Full Text] [Related]
92. Targeting Cytosolic Nucleic Acid-Sensing Pathways for Cancer Immunotherapies. Iurescia S; Fioretti D; Rinaldi M Front Immunol; 2018; 9():711. PubMed ID: 29686682 [TBL] [Abstract][Full Text] [Related]
93. The role of immunogenic cell death in gastrointestinal cancer immunotherapy (Review). Songjang W; Nensat C; Pongcharoen S; Jiraviriyakul A Biomed Rep; 2021 Oct; 15(4):86. PubMed ID: 34512974 [TBL] [Abstract][Full Text] [Related]
94. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade. Marchini A; Scott EM; Rommelaere J Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469 [TBL] [Abstract][Full Text] [Related]
95. From Benchtop to Bedside: A Review of Oncolytic Virotherapy. Choi AH; O'Leary MP; Fong Y; Chen NG Biomedicines; 2016 Aug; 4(3):. PubMed ID: 28536385 [TBL] [Abstract][Full Text] [Related]
97. Systems Biology Approaches for the Improvement of Oncolytic Virus-Based Immunotherapies. Tripodi L; Sasso E; Feola S; Coluccino L; Vitale M; Leoni G; Szomolay B; Pastore L; Cerullo V Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831638 [TBL] [Abstract][Full Text] [Related]
98. Restoring the Immunity in the Tumor Microenvironment: Insights into Immunogenic Cell Death in Onco-Therapies. Hernández ÁP; Juanes-Velasco P; Landeira-Viñuela A; Bareke H; Montalvillo E; Góngora R; Fuentes M Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34198850 [TBL] [Abstract][Full Text] [Related]
99. Inducing immunogenic cell death in immuno-oncological therapies. Ti D; Yan X; Wei J; Wu Z; Wang Y; Han W Chin J Cancer Res; 2022 Feb; 34(1):1-10. PubMed ID: 35355932 [TBL] [Abstract][Full Text] [Related]